Schering Canada ., filial de Schering-Plough Corporation, ha elegido el software de Business Intelligence de Cognos para dotar a sus departamentos de dirección y ventas con una sólida herramienta con aplicaciones de análisis y reporting.
NOTA DE PRENSA COGNOS CANADA
BURLINGTON, Mass., June 14 — Schering Canada Inc., a subsidiary of the Schering-Plough Corporation, has selected Cognos ReportNet to provide their sales organization and executive management with powerful reporting and analysis capabilities. Cognos is a leader in enterprise business intelligence (EBI) and corporate performance management solutions.
Schering Canada is engaged in manufacturing and marketing of pharmaceutical and health care products, including human and animal prescription drugs and over-the-counter products such as foot care and sun care products. By implementing Cognos ReportNet, sales representatives, sales managers, and executive management will be able to quickly and easily develop updated sales reports, analyze sales at the territory level to uncover trends in the customer base, analyze call volume activity, and eventually, develop and track metrics for the entire sales force.
«Working with Cognos solutions and services, Schering Canada is changing the way we work with our business data,» said Claude Mercier, director, decision support services, Schering Canada. «We are transitioning from a paper-based, spreadsheet-heavy process to a centralized data warehouse and a powerful Web reporting solution that our sales organization can leverage to understand the needs of customers, identify and act on sales opportunities, and improve sales force effectiveness.»
«The soaring R&D costs in the life sciences industry are mandating that companies find other ways of improving business processes and identifying cost savings,» said Bill Stevens, director of life sciences marketing, Cognos. «With Cognos Enterprise BI solutions, the world’s largest life sciences companies are gaining increased visibility in to the entire development process, enabling them boost sales performance, increase the efficiency of clinical trials, and ensure that business practices adhere to regulatory restriction — all factors that directly contribute to the growing bottom line growth.»
Pinche aquí para visitar el FORO SOBRE ENTERPRISE CONTENT MANAGEMENT y comentar esta información.
————————————————————————————————
Pinche aquí para visitar el FORO SOBRE BUSINESS INTELLIGENCE y comentar esta información.